Variability in the effect of muscle relaxants Factors - Anestezjologia i ...

Anestezjologia i Ratownictwo 2009; 3: 42-56
Anestezjologia • Ratownictwo • Nauka • Praktyka / Anaesthesiology • Rescue Medicine • Science • Practice
142. Ornstein E, Matteo RS, Schwartz AE, Jamdar SC, Diaz J. Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan)
in elderly surgical patients. Anesth Analg 1992; 74: 841-4.
143. McCarthy G, Elliott P, Mirakhur RK, Cooper R, Sharpe TD, Clarke RS. Onset and duration of action of vecuronium in the elderly:
comparison with adults. Acta Anaesthesiol Scand 1992; 36: 383-6.
144. Matteo RS, Ornstein E, Schwartz AE, Ostapkovich N, Stone JG. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426)
in elderly surgical patients. Anesth Analg 1993; 77: 1193-7.
145. Bevan DR, Fiset P, Balendran P, Law-Min JC, Ratcliffe A, Donati F. Pharmacodynamic behaviour of rocuronium in the elderly. Can J
Anaesth 1993; 40: 127-32.
146. Lien CA, Matteo RS, Ornstein E, Schwartz AE, Diaz J. Distribution, elimination, and action of vecuronium in the elderly. Anesth Analg
1991; 73: 39-42.
147. Matteo RS, Ornstein E, Schwartz AE, Ostapkovich N, Stone JG. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426)
in elderly surgical patients. Anesth Analg 1993; 77: 1193-7.
148. Zarday Z, Deery A, Tellis I, Soberman R, Foldes FF. Plasma and red cell cholinesterase activity in uremic patterns (effects of hemodialysis
and renal transplantation). J Med 1975; 6: 337-49.
149. Chang RY, Chern SC, Chiang YY, Liou MD, Tseng KF, Tsai SK. Neuromuscular interactions between succinylcholine and esmolol in
the rat. Acta Anaesthesiol Sin 1994; 32: 203-8.
150. Hunter JM, Jones RS, Utting JE. Use of atracurium in patients with no renal function. Br J Anaesth 1982; 54: 1251-8.
151. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with
azathioprine. Br J Anaesth 1987; 59: 995-1003.
152. Lepage JY, Malinge M, Cozian A, Pinaud M, Blanloeil Y, Souron R. Vecuronium and atracurium in patients with end-stage renal failure.
A comparative study. Br J Anaesth 1987; 59: 1004-10.
153. Sztark F, Cantini O, Bourdallé-Badie C, Gardien PL, Erny P. [Recovery of neuromusuclar blockade after continuous infusion of
cisatracurium in renal failure]. Ann Fr Anesth Réanim 2001; 20: 446-51.
154. Cook DR, Freeman JA, Lai AA, Kang Y, Stiller RL, Aggarwal S, Harrelson JC, Welch RM, Samara B. Pharmacokinetics of mivacurium
in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992; 69: 580-5.
155. Blobner M, Jelen-Esselborn S, Mann R, Kling M, Schneider G, Schneck HJ, Kochs E. [Neuromuscular and cardiovascular effect of
mivacurium in anesthesia induction in patients with renal failure]. Anasthesiol Intensivmed Notfallmed Schmerzther 1996; 31:
15-21.
156. Blobner M, Jelen-Esselborn S, Schneider G, Mann R, Kling M, Luppa P, Schneck HJ, Kochs E. Effect of renal function on neuromuscular
block induced by continuous infusion of mivacurium. Br J Anaesth 1995; 74: 452-4.
157. Miller RD, Stevens WC, Way WL. The effect of renal failure and hyperkalemia on the duration of pancuronium neuromuscular blockade
in man. Anesth Analg 1973; 52: 661-6.
158. Caldwell JE, Canfell PC, Castagnoli KP, Lynam DP, Fahey MR, Fisher DM, Miller RD. The influence of renal failure on the
pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide.
Anesthesiology 1989; 70: 7-12.
159. Wierda JMKH, Karliczek GF, Vandenbrom RHG, Pinto I, Kersten-Kleef UW, Meijer DK, Agoston S. Pharmacokinetics and cardiovascular
dynamics of pipecuronium bromide during coronary artery surgery. Can J Anaesth 1990; 37: 183-91.
160. Cameron EM, Lisbon A, Moorman R, Young JD. Prolonged neuromuscular blockade with pipecuronium in a patient with renal
insufficiency. Eur J Anaesthesiol 1994; 11: 237-9.
161. Khuenl-Brady K, Castagnoli KP, Canfell PC, Caldwell JE, Agoston S, Miller RD. The neuromuscular blocking effects and pharmacokinetics
of ORG 9426 and ORG 9616 in the cat. Anesthesiology 1990; 72: 669-74.
162. Wierda JMKH, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426,
a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J
Anaesth 1991; 38: 430-5.
163. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with
azathioprine. Br J Anaesth 1987; 59: 995-1003.
164. Fahey MR, Morris RB, Miller RD, Nguyen TL, Upton RA. Pharmacokinetics of ORG NC45 (norcuron) in patients with and without
renal failure. Br J Anaesth 1981; 53: 1049-52.
165. Lynam DP, Cronnelly R, Castagnoli KP, Canfell PC, Caldwell J, Arden J, Miller RD. The pharmacodynamics and pharmacokinetics of
vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 1988; 69:
227-31.
166. Slater RM, Pollard BJ, Doran BR. Prolonged neuromuscular blockade with vecuronium in renal failure. Anaesthesia 1988; 43: 250-1.
167. Beauvoir CPeray PDaures JP, Peschaud JL, D’Athis F. Pharmacodynamics of vecuronium in patients with and without renal failure:
a meta-analysis. Can J Anaesth 1993; 40: 696-702.
168. Sakamoto H, Takita K, Kemmotsu O, Morimoto Y, Mayumi T. Increased sensitivity to vecuronium and prolonged duration of its action
in patients with end-stage renal failure. J Clin Anesth 2001; 13: 193-7.
47